Aethlon Medical's diagnostic subsidiary Exosome Sciences plans to initiate a clinical study involving retired NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy - CTE - in living individuals. CTE is a neurodegenerative disease that has often been found in American football players, boxers and other individuals with a history of repetitive head trauma. Planned for initiation in Q2, the study intends to establish a clinical collaboration with up to 200 former professional football players and clinical investigators at multiple U.S. locations. If fully enrolled, the study would be the largest to date in former NFL players, who are at a high risk of suffering from CTE. The goal of the study will be to further validate a CTE biomarker candidate known as plasma exosomal tau, or a TauSome. The biomarker was previously studied as part of the first NIH-funded CTE research program which was managed by the Boston University CTE Center.